A total of 18 biotechs from the Class of 2003 class were acquired, five of them for two or more times the amount put in by investors. Of the remaining 13, at least 7 were sold for less than they had raised. (A) At the time of the deal, Axovan shareholders were eligible for further payments that could increase the total acquisition price to $187.7 million; $M; Source: BCIQ: BioCentury Online Intelligence